• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

F5 Gene Record

  • Summary
  • Interactions
  • Claims
  • F5 2153 Druggable Genome

    Alternate Names:

    2153
    COAGULATION FACTOR V
    F5
    FVL
    PCCF
    RPRGL1
    THPH2
    612309
    3542
    ENSG00000198734
    OTTHUMG00000034595
    P12259
    COAGULATION FACTOR VA
    FA5_HUMAN
    Proaccelerin, labile factor
    Activated protein C cofactor
    Coagulation factor V light chain
    Coagulation factor V heavy chain
    PA159
    T37510

    Gene Info:

    Target Class Miscellaneous
    Target Subclass Enzyme cofactor
    Target Main Class Other
    Gene Biotype PROTEIN_CODING
    (4 More Sources)

    Gene Categories: Category Details

    DRUGGABLE GENOME

    Publications:

    Straczek C et al., 2005, Prothrombotic mutations, hormone therapy, and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration., Circulation
    Wu O et al., 2005, Oral contraceptives, hormone replacement therapy, thrombophilias and risk of venous thromboembolism: a systematic review. The Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) Study., Thromb Haemost
    Cushman M et al., 2004, Estrogen plus progestin and risk of venous thrombosis., JAMA
    Kemmeren JM et al., 2004, Effect of second- and third-generation oral contraceptives on the protein C system in the absence or presence of the factor VLeiden mutation: a randomized trial., Blood
    Oger E et al., 2003, Differential effects of oral and transdermal estrogen/progesterone regimens on sensitivity to activated protein C among postmenopausal women: a randomized trial., Arterioscler Thromb Vasc Biol
    Kemmeren JM et al., 2002, Effect of second- and third-generation oral contraceptives on fibrinolysis in the absence or presence of the factor V Leiden mutation., Blood Coagul Fibrinolysis
    Legnani C et al., 2002, Venous thromboembolism in young women; role of thrombophilic mutations and oral contraceptive use., Eur Heart J
    Herrington DM et al., 2002, Factor V Leiden, hormone replacement therapy, and risk of venous thromboembolic events in women with coronary disease., Arterioscler Thromb Vasc Biol
    Kemmeren JM et al., 2002, Effects of second and third generation oral contraceptives and their respective progestagens on the coagulation system in the absence or presence of the factor V Leiden mutation., Thromb Haemost
    Høibraaten E et al., 2001, Hormone replacement therapy and acquired resistance to activated protein C: results of a randomized, double-blind, placebo-controlled trial., Br J Haematol
    Santamaría A et al., 2001, Risk of thrombosis associated with oral contraceptives of women from 97 families with inherited thrombophilia: high risk of thrombosis in carriers of the G20210A mutation of the prothrombin gene., Haematologica
    Spannagl M et al., 2000, Are factor V Leiden carriers who use oral contraceptives at extreme risk for venous thromboembolism?, Eur J Contracept Reprod Health Care
    Martinelli I et al., 1999, Interaction between the G20210A mutation of the prothrombin gene and oral contraceptive use in deep vein thrombosis., Arterioscler Thromb Vasc Biol
    Andersen BS et al., 1998, Third generation oral contraceptives and heritable thrombophilia as risk factors of non-fatal venous thromboembolism., Thromb Haemost
    Vandenbroucke JP et al., 1994, Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation., Lancet
    Crawley JT et al., 2007, The central role of thrombin in hemostasis., J Thromb Haemost
    Duggan C et al., 2003, Inherited and acquired risk factors for venous thromboembolic disease among women taking tamoxifen to prevent breast cancer., J Clin Oncol
    Abramson N et al., 2006, Effect of Factor V Leiden and prothrombin G20210-->A mutations on thromboembolic risk in the national surgical adjuvant breast and bowel project breast cancer prevention trial., J Natl Cancer Inst
  • ESTRONE SODIUM SULFATE   F5

    Interaction Score: 61.83

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16301339 16113779 15467059 14551147 12869355 12138364 12069454 12067913 11859850 11703344 11532625 10943572 10073976 9459317 7968118


    Sources:
    PharmGKB

  • RIVAROXABAN   F5

    Interaction Score: 5.15

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB FDA

  • DROTRECOGIN ALFA (ACTIVATED)   F5

    Interaction Score: 3.86

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Coagulation factor V inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • LUSUTROMBOPAG   F5

    Interaction Score: 2.58

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB FDA

  • AVATROMBOPAG   F5

    Interaction Score: 2.21

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB FDA

  • ELTROMBOPAG   F5

    Interaction Score: 2.21

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB FDA

  • THROMBIN   F5

    Interaction Score: 0.64

    Interaction Types & Directionality:
    activator (activating)

    Interaction Info:
    Trial Name ProFibrix B.V/
    Novel drug target Established target

    PMIDs:
    17635715


    Sources:
    TdgClinicalTrial

  • TAMOXIFEN   F5

    Interaction Score: 0.53

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    14512389 16818854


    Sources:
    PharmGKB FDA

  • Ensembl: ENSG00000198734

    • Version: 101_38

    Alternate Names:
    F5 Ensembl Gene Name

    Gene Info:
    Gene Biotype PROTEIN_CODING

    Publications:

  • TEND: P12259

    • Version: 01-August-2011

    Alternate Names:
    FA5_HUMAN Uniprot Id
    2153 Entrez Gene Id
    ENSG00000198734 Ensembl Gene Id

    Gene Info:
    Target Main Class Other
    Target Subclass Enzyme cofactor

    Publications:

  • TdgClinicalTrial: P12259

    • Version: January-2014

    Alternate Names:
    F5 Gene Symbol

    Gene Info:
    Target Class Miscellaneous
    Target Subclass Enzyme cofactor

    Publications:

  • PharmGKB: F5

    • Version: 18-August-2020

    Alternate Names:
    PA159 PharmGKB ID

    Gene Info:

    Publications:
    Abramson N et al., 2006, Effect of Factor V Leiden and prothrombin G20210-->A mutations on thromboembolic risk in the national surgical adjuvant breast and bowel project breast cancer prevention trial., J Natl Cancer Inst
    Duggan C et al., 2003, Inherited and acquired risk factors for venous thromboembolic disease among women taking tamoxifen to prevent breast cancer., J Clin Oncol
    Santamaría A et al., 2001, Risk of thrombosis associated with oral contraceptives of women from 97 families with inherited thrombophilia: high risk of thrombosis in carriers of the G20210A mutation of the prothrombin gene., Haematologica

  • HingoraniCasas: ENSG00000198734

    • Version: 31-May-2017

    Alternate Names:
    ENSG00000198734 Gene Symbol
    F5 Ensembl Id

    Gene Info:

    Gene Categories:
    DRUGGABLE GENOME

    Publications:

  • ChemblInteractions: F5

    • Version: chembl_23

    Alternate Names:
    F5 GENE_SYMBOL
    Coagulation factor V UNIPROT
    Coagulation factor V heavy chain UNIPROT

    Gene Info:

    Publications:

  • TTD: Coagulation factor Va

    • Version: 2020.06.01

    Alternate Names:
    F5 TTD Gene Abbreviation
    T37510 TTD Target ID

    Gene Info:

    Publications:

  • FDA: F5

    • Version: 04-September-2020

    Alternate Names:

    Gene Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21